Evidence map›Paper›PMID 41978416›Full record

ReviewBeijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences2026

[Robotic gastrectomy: Research progress and practical challenges].

Bin Li, Han Liang

Abstract readReviewEnglish Abstract
In one paragraph

Review in Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Bin LiDepartment of Gastric Surgery, Tianjin Medical University Cancer Institute & Hospital; National Clinical Research Center for Cancer; Tianjin Key Laboratory of Digestive Cancer; Tianjin's Clinical Research Center for Cancer, Tianjin 300060, China.
Han LiangDepartment of Gastric Surgery, Tianjin Medical University Cancer Institute & Hospital; National Clinical Research Center for Cancer; Tianjin Key Laboratory of Digestive Cancer; Tianjin's Clinical Research Center for Cancer, Tianjin 300060, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gastric cancer is one of the malignant tumors with high incidence and mortality rates globally, with China ranking among the top 5 in both case numbers and deaths. With the popularization of laparoscopic technology and surgical robotic systems, gastric cancer surgery has entered the era of minimally invasive procedures. Robotic gastrectomy (RG) demonstrates unique value in complex lymph node dissection and digestive tract reconstruction, outperforming laparoscopic gastrectomy (LG) in terms of intraoperative blood loss, recovery speed, and certain complications. However, the longer operation time and higher costs remain disadvantages of RG. Currently, both domestic and international guidelines include RG in the treatment indications for early and some locally advanced gastric cancer, emphasizing that it should be performed in experienced medical centers. Meanwhile, new technologies such as indocyanine green (ICG) near-infrared imaging-guided lymph node dissection, reduced-port/single-port surgery, 5G remote surgery and integration with artificial intelligence are continuously emerging, driving RG towards precision and intelligence. This article systematically reviews clinical research and guideline consensus from both domestic and international sources, focusing on evaluating the technical characteristics, learning curve, short-term/long-term efficacy and expansion of indications for RG. It analyzes its main limitations and provides a prospective discussion on future development directions.

Indexed as

GastrectomyRobotic Surgical ProceduresStomach NeoplasmsHumansLaparoscopyLymph Node ExcisionLaparoscopyMinimally invasive surgical proceduresRobotic surgical proceduresStomach neoplasms

Identifiers

PMID41978416
PMCPMC13077320

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.